Zhongzhi Pharmaceutical Holdings Limited provides earnings guidance for the six months ended June 30, 2023. The Board informed the shareholders of the Company and potential investors that based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 ("FP2023"), it is expected that the Group will record a significant increase of around 70% in the net profit for FP2023 as compared with the corresponding period in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.18 HKD | -3.28% | -3.28% | -16.90% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-16.90% | 135M | |
+20.81% | 43.34B | |
+20.44% | 21.96B | |
+13.30% | 14.09B | |
+12.97% | 13.64B | |
+39.74% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+9.64% | 5.22B |
- Stock Market
- Equities
- 3737 Stock
- News Zhongzhi Pharmaceutical Holdings Limited
- Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023